Last updated: 2026-09-07 10:36:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
OKYO Pharma Limited (OKYO) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.56, with a market capitalisation of $85.02M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.34 to $3.20. This page covers its latest market performance, valuation, price trends and company information.
$85.02M | |
$1.55 | |
$7.00 | |
$0.81 | |
$1.55 | |
31.05K | |
-- | |
-- | |
$3.20 | |
$1.34 | |
-- | |
-- |
OKYO Pharma Limited (OKYO) last closed at $1.55 as of 2026-09-04 23:40:00, unchanged from the previous close of $1.55.
During the latest regular trading session, OKYO traded between $0.81 and $7.00, with a volume of 31.05K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, OKYO Pharma Limited (OKYO) moved from $1.65 to $1.56, representing a decline of 5.76% ($0.09).
The stock traded between $1.52 and $1.65 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 58.97 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 11.6%
OKYO is currently trading at $1.56, placing it 11.6% of the way from its 52-week low of $1.34 to its 52-week high of $3.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of OKYO Pharma Limited (OKYO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.